CDR-Life Appoints Dimitrios Chondros as Chief Medical Officer to Advance T Cell Engager Platform
Key Insights
CDR-Life has appointed Dimitrios Chondros, MD, as Chief Medical Officer to oversee clinical development of the company's M-gager (search)® T cell engager platform for cancer and autoimmune diseases.
Dr. Chondros brings over 20 years of global drug development experience, including previous roles as Chief Medical Officer at Halozyme and Global Development Team Leader for Avastin® at Genentech.
The appointment comes as CDR-Life advances its first oncology program in clinical trials and expands its pipeline of highly selective T cell engagers targeting solid cancers and autoimmune diseases.
CDR-Life, a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs), has appointed Dimitrios Chondros, MD, as Chief Medical Officer to lead the advancement of its proprietary M-gager (search)® platform for treating cancer and autoimmune diseases.
Leadership Appointment Strengthens Clinical Strategy
Dr. Chondros will oversee CDR-Life's clinical development, clinical operations, medical affairs and translational strategy. His appointment follows a period of significant progress for the company as it continues to translate its M-gager (search) platform into clinical-stage programs.
The new Chief Medical Officer brings more than 20 years of global drug development, medical leadership and oncology expertise across biotech and pharmaceutical organizations, spanning early clinical development through late-stage programs and global regulatory engagements.
Extensive Industry Experience
Dr. Chondros previously served as Chief Medical Officer for Halozyme and was Global Development Team Leader for Avastin® in colorectal cancer at Genentech. He studied medicine at RWTH University Aachen, Germany and University Zürich, Switzerland, and is a board-certified general surgeon.
"Dimitrios is a highly respected clinical leader with a rare combination of hands-on drug development experience, global leadership perspective and medical expertise," said Christian Leisner, PhD, Chief Executive Officer of CDR-Life. "As we progress our M-gager (search) programs in the clinic and expand our pipeline across oncology and autoimmune diseases, Dimitrios' leadership will be instrumental in guiding our clinical strategy and execution."
M-gager Platform Development
CDR-Life's M-gager (search) platform represents what the company describes as a compelling evolution in multispecific T cell engagers, combining precision, potency and developability. The platform delivers TCEs against challenging but clean targets through what the company characterizes as unparalleled binding-specificity.
"CDR-Life's M-gager (search)® platform represents a compelling evolution in multispecific T cell engagers, combining precision, potency and developability," said Dr. Chondros. "I look forward to working with the team to translate this differentiated science into meaningful clinical outcomes for patients."
Clinical Progress and Pipeline
The company currently has its first oncology program in clinical trials and is advancing a pipeline of potent and selective TCE therapeutics for solid cancers and autoimmune diseases. CDR-Life maintains a longstanding partnership with Boehringer Ingelberg on a molecule derived from the M-gager (search) platform, which is now in Phase 2 trials, demonstrating the potential of the company's antibody-derived molecules.
The biotechnology company is backed by leading cross-Atlantic investors and remains committed to bringing life-changing, disease-modifying medicines to patients globally through its targeted approach to T cell engager development.